← All trials
NCT07081334
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2022
- Primary completion
- Apr 29, 2024
- Completion date
- Jan 30, 2025
- First posted
- Jul 23, 2025
- Last posted
- Jul 23, 2025
- Enrollment
- 41
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PosvaxLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.